Aktuellt
SENASTE
There is a fair amount of activity to report for BB Biotech’s third quarter. The share price premium has dipped to 5%; a holding company has been taken private, resulting in a large cash inflow, giving BB Biotech flexibility to act on interesting investment opportunities; products in holding companies have seen approval and trial progression; and finally, the Inflation Reduction Act was signed into law by President Biden.
LÄS MER
